Document Detail


Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging.
MedLine Citation:
PMID:  15688112     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New anticancer therapeutics that target tumor blood vessels promise improved efficacy and tolerability in humans. Early phase 1 drug trials have shown that the maximum tolerated dose may be inappropriate for more advanced clinical studies with efficacy endpoints. More advanced clinical trials have demonstrated that morphologic assessments of tumor response are of limited value for gauging the efficacy of treatment. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can serve as pharmacodynamic indicator of biological activity for antivascular cancer drugs by helping to define the biologically active dose. DCE-MRI studies may also predict the efficacy of treatment on the basis of changes observed. If DCE-MRI is to be used for the selection of antivascular drugs that advance into efficacy trials, then it will be necessary to develop standardized approaches to measurement and robust analytic approaches with clear accepted endpoints specified prospectively that have biological validity. Such developments will be essential for multicenter trials in which it will be necessary to establish effective cross-site standardization of measurements and evaluation.
Authors:
A R Padhani; M O Leach
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Abdominal imaging     Volume:  30     ISSN:  0942-8925     ISO Abbreviation:  Abdom Imaging     Publication Date:    2005 May-Jun
Date Detail:
Created Date:  2005-06-20     Completed Date:  2005-09-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9303672     Medline TA:  Abdom Imaging     Country:  United States    
Other Details:
Languages:  eng     Pagination:  324-41     Citation Subset:  IM    
Affiliation:
Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, United Kingdom. anwar.padhani@paulstrickland-scannercentre.org.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use*
Contrast Media / pharmacokinetics
Gadolinium DTPA / diagnostic use
Humans
Image Enhancement
Magnetic Resonance Imaging / methods*
Neoplasms / diagnosis,  drug therapy*
Neovascularization, Pathologic / drug therapy,  physiopathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Contrast Media; 80529-93-7/Gadolinium DTPA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Short-term complications of retrograde transvenous obliteration of gastric varices in patients with ...
Next Document:  Complications of radiofrequency ablation in hepatocellular carcinoma.